We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The government has immediately authorised the NHS to use the world’s first coronavirus treatment proven to reduce the risk of death.
Key MHRA advice and guidance issued so far on medicines safety and pharmacovigilance, including on reporting to the Yellow Card Scheme.
Serious liver injury has been reported during treatment with pirfenidone in the first year after initiation, including 2 cases with a fatal outcome. Measure alanine aminotransferase (ALT), aspartate aminotransferase (AST), a…
(Novartis Consumer Health UK Limited and Actavis Group PTC EHF): Product reclassified from P to POM due to safety concerns – class 2 action within 48 hours (EL (15)A/01)
Caution is required if prescribing febuxostat in patients with pre-existing major cardiovascular disease, particularly, in those with evidence of high urate crystal and tophi burden or those initiating urate-lowering therapy…
Information for healthcare professionals on diphtheria anti-toxin (DAT).
Clinical guidance on myocarditis and pericarditis after COVID-19 vaccination for healthcare professionals.
Information for healthcare professionals on myocarditis and pericarditis following COVID-19 vaccination.
Employment Tribunal decision.
Applications received to amend the specification of a patent under sections 27 and 75 before the court and the Office.
Upper Tribunal Administrative Appeals Chamber decision by Judge Bano on 7 June 2017.
A summary of the evidence on efficacy of Evusheld as a prophylactic treatment for coronavirus (COVID-19) considered by the RAPID C-19 Oversight Group.
The possible relationship between exposure to silica and asbestos and development of anti-neutrophil cytoplasmic antibodies - associated vasculitis.
This paper explores anti-blasphemy activism in the UK, its networks and international influences, and looks at 3 flashpoint incidents.
A report on using neutralising monoclonal antibodies (nMABs) in a prophylaxis setting for patients with highest-risk of hospitalisation or death from COVID-19.
Seeking views on revisions to the voluntary guidelines for operators carrying passengers to designated sporting events.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).